Boston, Massachusetts, USA, September 1, 2026
Vertex Pharmaceuticals Incorporated has completed its acquisition of Crinetics Pharmaceuticals, Inc., strengthening its position in endocrinology and adding a commercial-stage rare endocrine disease medicine and an investigational late-stage therapy to its pharmaceutical portfolio. The transaction, previously announced in July 2026, was completed after satisfaction of customary closing conditions and receipt of required regulatory approvals. The acquisition was valued at approximately $10 billion in equity value and represents a major expansion of Vertex’s therapeutic focus beyond its established franchises. Through the transaction, Vertex gains PALSONIFY (paltusotine), an oral nonpeptide somatostatin receptor type 2 antagonist approved in the United States for adults with acromegaly, as well as atumelnant, an investigational oral melanocortin-4 receptor antagonist being developed for congenital adrenal hyperplasia and other potential endocrine indications.
Vertex Adds Commercial Rare-Disease Medicine
The acquisition gives Vertex immediate access to PALSONIFY (paltusotine), an orally administered treatment for adults with acromegaly, a rare endocrine disorder caused by excessive growth hormone production. Paltusotine works by selectively blocking somatostatin receptor type 2 (SST2), reducing signaling that contributes to excessive growth hormone and insulin-like growth factor-1 activity. The medicine provides Vertex with an established commercial opportunity in a rare endocrine disease while complementing the company’s existing capabilities in specialty medicines. Crinetics had developed paltusotine as a potential oral alternative to injectable therapies commonly used in acromegaly management. The addition of a marketed endocrine product represents an important strategic change for Vertex as the company seeks to build a new endocrinology growth pillar alongside its established therapeutic franchises. The transaction also brings Crinetics’ development and commercial expertise into Vertex. Vertex expects the combination to provide opportunities to expand access to paltusotine and potentially investigate its use in additional endocrine conditions where SST2 signaling may play a role.
Atumelnant Expands Vertex Endocrine Pipeline
Beyond the commercial-stage asset, the acquisition adds atumelnant, a potentially first-in-class oral MC4R antagonist that remains investigational. Atumelnant is being developed for congenital adrenal hyperplasia (CAH), a genetic disorder affecting adrenal hormone production. The candidate is designed to act on the melanocortin pathway involved in regulating adrenal androgen production. Atumelnant therefore provides Vertex with a development-stage asset that could address a significant unmet need in endocrine disorders. The program expands Vertex’s rare-disease pipeline while creating opportunities to leverage the company’s global clinical-development and regulatory capabilities. However, atumelnant is not an approved medicine, and its safety and efficacy have not been established for marketing purposes. The clinical-development program will need to generate additional evidence before any potential regulatory submission or approval. The acquisition should therefore be viewed as a strategic pipeline expansion rather than confirmation that the investigational candidate will reach the market.
Advertisement
Crinetics Acquisition Establishes New Growth Pillar
Vertex said the acquisition establishes endocrinology as a new growth pillar for the company and expands its potential to develop medicines for serious rare diseases. The transaction combines Crinetics’ endocrine-focused research and development capabilities with Vertex’s global infrastructure, manufacturing expertise and commercial organization. Following completion of the transaction, Vertex also announced changes to its executive leadership team. Crinetics’ President and Chief Executive Officer, Scott Struthers, will join Vertex’s leadership structure and oversee the company’s endocrinology strategy, reflecting the importance Vertex places on the newly acquired business. The acquisition demonstrates the continuing role of M&A in pharmaceutical pipeline expansion, particularly when established companies seek commercially validated products and differentiated clinical-stage assets. For Vertex, acquiring Crinetics provides both an immediate commercial endocrinology opportunity through paltusotine and a longer-term development opportunity through atumelnant. The completed transaction also illustrates how pharmaceutical companies can use strategic acquisitions to enter therapeutic areas with specialized biology and established clinical expertise rather than building every capability internally. With paltusotine and atumelnant now part of its portfolio, Vertex has expanded its rare-disease presence and created a new platform for potential growth in endocrinology. The long-term value of the transaction will depend on commercial performance of PALSONIFY, continued development of atumelnant and the company’s ability to advance additional endocrine programs.
Source: Vertex Pharmaceuticals, Crinetics Pharmaceuticals press release
